Albemarle Corporation (ALB): what the price requires

At today's price, Albemarle Corporation (ALB) is priced for today's economics sustained for ~5.8 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/ALB

Headline

FieldValue
TickerALB
CompanyAlbemarle Corporation
Current price$125.66/sh
CompositionEnergy Storage 53% / Specialties 27% / Ketjen 21%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed15.1%
Operating margin (mid-cycle)18.6%
Margin compression implied-3.5pp
Trailing margin (depressed year)1.6%
Must persist for5.8y
Multiple paid16x mid-cycle operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 12.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.6 years.

Reconcile: at the x-ray's 9.3% required return this reads ~8.6%/yr; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.24σ
sustained it ~5.8 years at this level29%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.68x3expensive
Earnings3.10x3expensive
Relative1.81x3expensive
Growth1.03x3expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.

Per-Model Detail (n=12)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$121.671.03xyesFCF base $0.6B, growth 10% (input: historical growth), terminal g 4.0%, WACC 8.6%, 6yr projection
DCF Exit MultipleGrowth$135.040.93xyesExit EV/EBITDA: 29.7x / 31.7x / 33.7x (bear / base = today's held flat / bull), 6yr
Relative ValuationRelative$69.491.81xyesP/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$83.051.51xyesReference only (book value floor): BV/sh $83.05, ROE negative
Two-Stage Excess ReturnAsset$74.741.68xyesReference only (book value with convergence): BV/sh $83.05, ROE converges to ke
Discounted Future Market CapGrowth$105.961.19xyesRev $5.5B, growth 10% (input: historical growth; tapered), Terminal P/S: 2.2x / 2.7x / 3.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$34.913.60xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.57B × (1−21%) / WACC 8.6% → EPV (no growth)
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$25.464.94xyesEBITDA $0.50B × sector EV/EBITDA 8.0x
FCF YieldEarnings$44.262.84xyesFCF $577.3M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$40.513.10xyesSBC-adj FCF $0.54B (FCF $0.58B − SBC $0.04B) capitalized at Kₑ
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$16.437.65xyesBV $83.05 × (ROIC 1.7% / WACC 8.6%)
P/Sales SectorRelative$69.491.81xyesRevenue $5.49B × sector P/S 1.5x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$897.8m
Net debt / NOPAT (after-tax)1.19x
Net debt / operating income (pre-tax)0.94x
Share count CAGR (dilution)0.2%
Burning cashno

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 18.6%); the trailing year was depressed.

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

The lithium cycle has turned. First-quarter 2026 net sales rose 33 percent to $1.43 billion and adjusted EBITDA jumped 148 percent to $664 million, with net income of $319 million against $41 million a year earlier.

Trailing earnings are still depressed, so the price is read against mid-cycle margins. On that basis the market is paying about 20 times normalized operating income, embedding ceiling-level growth held for roughly eight years.

Earnings swing enormously with the lithium price. Management's own scenarios run from about $0.9 billion of EBITDA at $10 per kilogram to over $4 billion at $30, so the entire thesis rides on a commodity price the company does not control.

Bull Case

The earnings trajectory has inflected off a brutal trough, and the inflection is steep. First-quarter 2026 net sales rose 33 percent to $1.43 billion and adjusted EBITDA jumped 148 percent to $664 million, with net income attributable to the parent of $319 million against just $41 million a year earlier. The Energy Storage segment, just over half the company, led the recovery, with net sales up 70 percent to $891 million and adjusted EBITDA up 196 percent to $551 million, reflecting both higher lithium pricing and volumes and the company's cost and productivity gains. After a stretch where the filing describes "decreased earnings from the Energy Storage segment, driven by lower average lithium market prices" (FY2025 10-K, accession 0000915913-26-000018), that line is now the engine again.

The driver is a genuine commodity recovery. Spot lithium collapsed to roughly $8,000 per metric ton by mid-2025 and had recovered to about $21,000 by May 2026. Albemarle is one of the lowest-cost, largest-scale lithium producers in the world, with long-lived resources, so it has the operating leverage to convert a price recovery into outsized profit, which is exactly what the first quarter showed. The inversion reads the price against mid-cycle rather than trough margins for this reason: the trough is not the normal state of the business.

Management has used the downturn to harden the balance sheet, which positions the company for the upcycle. Albemarle cut capital expenditures sharply, with first-quarter capex of only $99 million against operating cash flow of $346 million and free cash flow of $248 million, and it sold non-core assets, the Eurecat and a Ketjen stake, for $648 million of net proceeds, enabling about $1.3 billion of debt reduction. Net debt is now modest relative to mid-cycle earnings. A low-cost producer that survived the trough with a stronger balance sheet, into a recovering lithium price and continued long-term demand from electrification and energy storage, has the financial flexibility to compound as the cycle turns up.

Bear Case

The capital-allocation picture tells you how little control management has over the outcome, and how much the downturn forced its hand. Albemarle has had to slash capital expenditures to roughly $99 million in the quarter, sell non-core businesses to raise $648 million, and use the proceeds to cut $1.3 billion of debt, all to, in the filing's words, "maintain financia"l flexibility "during the continued uncertainty surrounding the global economy, including lithium market pricing" (FY2025 10-K, accession 0000915913-26-000018). That is a company on the defensive: cutting the growth investment that a long-cycle resource business depends on, and selling assets to protect the balance sheet. The dividend was maintained through the trough, but at a deeply negative trailing operating margin, the cash to pay it had to come from somewhere, and asset sales and capex cuts are not a sustainable source.

The earnings depend almost entirely on a price the company cannot set. Management's own 2026 scenarios make the swing explicit: at about $10 per kilogram of lithium carbonate equivalent, total net sales run $4.1 to $4.3 billion with adjusted EBITDA of $0.9 to $1.0 billion; at around $30 per kilogram, sales rise to $7.5 to $7.8 billion and EBITDA to $4.2 to $4.4 billion. A four-to-one swing in EBITDA across a plausible price band means the equity is essentially a leveraged bet on the lithium spot price, and the filing notes that supply and demand are "influenced by changes in international investment patterns, various political developments and macro-economic" factors (same filing).

The valuation gives the cyclical bet no margin for the price to fall back. The asset, earnings-power and peer-multiple methods all read the stock as expensive; only the forward-growth frame reaches the price. At about 20 times mid-cycle operating income, the price embeds ceiling-level growth sustained for roughly eight years, a pace only about 19 percent of comparable companies held that long, and it does so on normalized margins that assume the lithium recovery is durable. New low-cost supply from competitors, a stall in electric-vehicle demand growth, or a renewed price slide would push the company back toward the trough it just escaped. Buying a recovered cyclical at a multiple that prices durable mid-cycle compounding is the classic way to overpay near the top of the rebound.

Valuation

Trailing earnings are depressed by the cycle, with a negative trailing operating margin, so the price is read against the company's own through-the-cycle margins on current revenue, near 18.6 percent mid-cycle, rather than the trough quarter. On that basis the market is paying about 20 times normalized operating income, which inverts to ceiling-level operating growth held for roughly eight years. The asset, earnings-power and peer-multiple frames all read the price as expensive; only the forward-growth DCF reaches it, and the blended central value across methods sits near $83 against the $160.35 price (June 27, 2026).

The valuation question is really a commodity question. The implied pace is within what Albemarle has delivered in better times, so the rate is not the stretch; the stretch is the duration, since only about 19 percent of comparable companies sustained ceiling growth for eight years, and the assumption that mid-cycle margins hold. The first quarter showed how fast the economics improve when lithium recovers, with adjusted EBITDA up 148 percent, but management's scenarios, EBITDA of roughly $0.9 billion at $10 per kilogram versus over $4 billion at $30, show the result is dominated by a price the company does not control. The balance sheet is now in better shape after $1.3 billion of debt reduction and the asset sales, so leverage is no longer the acute risk it was. The investment case is therefore a bet that the lithium price recovery is durable and that Albemarle's low-cost position lets it earn mid-cycle margins through the next decade. If lithium holds near recovered levels, the normalized earnings can grow into the price; if the price slides back toward the trough, a multiple that already prices durable mid-cycle compounding has a long way down toward the static methods.

Catalysts

The lithium price is the dominant catalyst. Spot lithium recovered from about $8,000 per metric ton in mid-2025 to roughly $21,000 by May 2026, and the company's earnings move enormously with it: management's scenarios span adjusted EBITDA of about $0.9 billion at $10 per kilogram to over $4 billion at $30. The lithium price trajectory is the single most important thing to watch, since it sets the entire result.

Earnings recovery and cost execution are the operational catalysts. First-quarter adjusted EBITDA rose 148 percent and Energy Storage EBITDA rose 196 percent on price, volume and cost gains. The sustainability of the cost and productivity improvements, and continued volume growth, are the items that determine how much of any price recovery falls to the bottom line. Quarterly results are the proof point.

Balance-sheet and capital discipline are the swing factors. Albemarle cut capex to about $99 million in the quarter, sold Eurecat and a Ketjen stake for $648 million, and reduced debt by $1.3 billion. Watch free cash flow, the pace of any further asset sales, capital-spending decisions, and the dividend, since these show whether the company can fund itself and reinvest for the upcycle without straining the balance sheet. A renewed lithium price decline or a stall in electric-vehicle demand growth is the principal downside trigger to monitor.

Peer Cohorts (Per Segment, With Filing Citations)

Energy Storage (reported)

Specialties (reported)

Ketjen (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive ALB report on boothcheck